Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.

1 report, 1 independent Updated Aug 13

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck

How it developed

Newest first. Tap a step to see who reported it.

Jun 8Jefferies maintained a Buy rating on Merck & Co., citing revenue growth from Keytruda and vaccine sales stability.Sub-event
Jun 8Merck's stock change was less than S&P 500's daily loss and outperformed the Medical sector loss on July 19, 2025.Sub-event
Aug 13Market upward trend influenced Merck's share increase, aided by Health Canada approval and Fed rate cuts.1 source
- Simply Wall St.

Keep exploring

Part of

Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.

Also in this story

Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.Aug 16

All 4 developments

The entities involved

Merck
public company in Indonesia
- Merck launched its GBA Innovation Center in Shenzhen and signed an agreement to establish a center in Hong Kong.Wed 22:42
- Moderna and Merck announced the successful outcome of their Phase 3 combined treatment trials involving a new cancer vaccine and Keytruda.Sun 12:39

Coverage

Newest first; wire copies grouped

Aug 13Simply Wall St.Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment Merck recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy